BPMC vs. ARGX, ONC, BNTX, TEVA, SMMT, ITCI, GMAB, RDY, ASND, and VTRS
Should you be buying Blueprint Medicines stock or one of its competitors? The main competitors of Blueprint Medicines include argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.
Blueprint Medicines vs. Its Competitors
argenex (NASDAQ:ARGX) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.
60.3% of argenex shares are owned by institutional investors. 2.4% of argenex shares are owned by insiders. Comparatively, 4.2% of Blueprint Medicines shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, argenex had 9 more articles in the media than Blueprint Medicines. MarketBeat recorded 17 mentions for argenex and 8 mentions for Blueprint Medicines. Blueprint Medicines' average media sentiment score of 1.23 beat argenex's score of 0.93 indicating that Blueprint Medicines is being referred to more favorably in the news media.
argenex presently has a consensus price target of $729.93, suggesting a potential upside of 32.42%. Blueprint Medicines has a consensus price target of $128.06, suggesting a potential downside of 0.09%. Given argenex's stronger consensus rating and higher probable upside, equities analysts plainly believe argenex is more favorable than Blueprint Medicines.
argenex has a net margin of 40.20% compared to Blueprint Medicines' net margin of -27.70%. argenex's return on equity of 16.15% beat Blueprint Medicines' return on equity.
argenex has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500.
argenex has higher revenue and earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.
Summary
argenex beats Blueprint Medicines on 13 of the 17 factors compared between the two stocks.
Get Blueprint Medicines News Delivered to You Automatically
Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BPMC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Blueprint Medicines Competitors List
Related Companies and Tools
This page (NASDAQ:BPMC) was last updated on 6/30/2025 by MarketBeat.com Staff
